Targeted therapy for the treatment of advanced non-small cell lung cancer: A review of the epidermal growth factor receptor antagonists

Chest

Volumn 128, Issue 6, 2005, Pages 3975-3984

  Silvestri, Gerard A ^a   Rivera, M Patricia ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Epidermal growth factor receptor; Lung cancer; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EDM 72000; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; GEMCITABINE; IMMUNOGLOBULIN G1 ANTIBODY; IRINOTECAN; NAVELBINE; PACLITAXEL; PANITUMUMAB; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACNE; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER PALLIATIVE THERAPY; CHILL; CLINICAL TRIAL; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DYSPNEA; ENZYME INHIBITION; FEVER; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LIGAND BINDING; LUNG CANCER; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; NEUTROPENIA; PATIENT SELECTION; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; SYSTEMATIC REVIEW; TARGET CELL; VOMITING;

EID: 30344446398     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.6.3975     Document Type: Review

References (53)

1. Cancer Facts & Figures 2004. Atlanta, GA: American Cancer Society, 2004
2. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics 2000. CA Cancer J Clin 2000; 50:7-33
3. Jemal A, Murray T, Samuels A, et al. Cancer statistics 2003. CA Cancer J Clin 2003; 53:5-26
4. Landis SH, Murray T, Bolden S, et al. Cancer statistics 1999. CA Cancer J Clin 1999; 49:8-31
5. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22:330-353
6. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-2103
7. Fossella FV, Lynch T, Shepherd FA. Second line chemotherapy for NSCLC: establishing a gold standard. Lung Cancer 2002; 38(suppl):S5-S12
8. Schiller JH, Harrington D, Belani CP, et al, for the Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98
9. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311:899-909
10. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-1597
11. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 2003; 30:3-14
12. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000; 60(suppl 1):15-23
13. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232
14. Veale D, Kerr N, Gibson GJ, et al, The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993; 68:162-165
15. Cerny T, Barnes DM, Hasleton P, et al. Expression of epidermal growth factor receptor (EGF-R) in human lung tumors. Br J Cancer 1986; 54:265-269
16. Tateishi M, Ishida T, Mitsudomi T, et al. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 1990; 50:7077-7080
17. Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor α is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997; 3:515-522
18. Baselga J. New technologies in epidermal growth factor receptor-targeted cancer therapy: an overview of novel therapeutic agents in development. Signal 2000; 1:12-21
19. Herbst RS, Kim ES, Harari PM. IMC-C225: an anti-epidermal growth factor receptor monoclonal antibody for the treatment of head and neck cancers. Expert Opin Biol Ther 2001; 1:719-732
20. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18:904-914
21. Bonner JA, Giralt PM, Harari R, et al. Phase III study of high dose radiation with or without cetuximab in the treatment of locoregionally advanced squamous cell cancer of the head and neck (SCCHN) [abstract]. Am Soc Clin Oncol 2004. Available at: http://www.asco. org/ac/1,1003,_12-002636-00_18-0026-00_19- 00213,00.asp. Accessed July 2004
22. Rosell R, Daniel C, Ramlau R, et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC) [abstract] Proc Am Soc Clin Oncol 2004; 23:618
23. Kim ES, Mauer AM, Tran HT, et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report [abstract]. Proc Am Soc Clin Oncol 2003; 22:642
24. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001; 8:3-9
25. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237-2246
26. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158
27. Ochs J, Grous J, Warner KL. Final survival and safety results for 21,064 non-small cell lung cancer (NSCLC) patients who received compassionate use gefitinib (Iressa®) in a United States expanded access program (EAP) [abstract]. Proc Am Soc Clin Oncol 2004; 23:628
28. Shepherd FA, Pereira J, Ciuleanu TE, et al. Erlotinib in previously tested non-small cell lung cancer. N Engl J Med 2005; 353:123-132
29. Cella D, Eton DT, Fairclough DL, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 2002; 55:285-295
30. Douillard J-Y, Giaccone G, Horai T, et al. Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1). Proc Am Soc Clin Oncol 2002; 21(pt 1):299a
31. Natale RB, Skarin AT, Maddox A-M, et al. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. Proc Am Soc Clin Oncol 2002; 21(pt 1):292a
32. Bailey R, Kris M, Wolf M, et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ('Iressa', ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res 2003; 44 (2nd ed):1362
33. Bailey LR, Janas M, Schmidt K, et al. Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy. Proc Am Soc Clin Oncol 2004; 23:618
34. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139
35. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500
36. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306-13311
37. Perez-Soler R, Chachoua A, Huberman M, et al. Final results from a phase II study of erlotinib (Tarceva™) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy. Lung Cancer 2003; 41(suppl 2):S246
38. Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144:1169-1176
39. Rowinski EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human antiepidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22:3003-30015
40. Saltz LB, Kies M, Abbruzzese L, et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies [abstract]. Proc Am Soc Clin Oncol 2003; 22:204
41. Herbst RS, LoRusso PM, Purdoin M, et al. Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer 2003; 4:366-369
42. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003; 361:137-139
43. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22:777-784
44. Johnson DH, Herbst R, Giaccone G, et al. ZD1839 ("Iressa") in combination with paclitaxel & earboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann Oncol 2002; 13(suppl 5):127-128
45. Govindan R. Management of patients with non-small cell lung cancer and poor performance status. Curr Treat Options Oncol 2003; 4:55-59
46. Gridelli C, Maione P, Castaldo V, et al. Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. Br J Cancer 2003; 89:1827-1829
47. Williams CC, Haura EB, Antonia SJ, et al. Phase II trial of docetaxel and gefitinib as first-line therapy for elderly patients with advanced non-small cell lung cancer (ANSCLC). Proc Am Soc Clin Oncol 2004; 23:698
48. Dickson NR, Hainsworth JD, Spigel DR, et al. Single agent gefitinib in poor performance status patients with previously untreated advanced non-small cell lung cancer: a Minnie Pearl Cancer Research Network phase II trial. Proc Am Soc Clin Oncol 2004; 23:634
49. Zinner R, Govindan R, Wozniak AJ, et al. Compassionate use experience with gefitinib in poor performance (PS) patients with advanced non-small-cell lung cancer (NSCLC) treated in an expanded access program (EAP). Proc Am Soc Clin Oncol 2004; 23:633
50. Slichenmyer WJ, Elliott WL, Fry DW. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol 2001; 5(suppl 16):80-85
51. Shaw JP, Akiyoshi DE, Arrigo DA, et al. Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J Biol Chem; 1991; 266:211-224
52. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-small cell lung cancer; version 1.2004. Available at: www.nccn.org/professionals/physician _gls/license_agreement.asp. Accessed June 18, 2004
53. Schroen AT, Detterbeck FC, Crawford R, et al. Beliefs among pulmonologists and thoracic surgeons in the therapeutic approach to non-small cell lung cancer. Chest 2000; 118:129-137